Home Analytical precision of the Urolizer® for the determination of the BONN-Risk-Index (BRI) for calcium oxalate urolithiasis and evaluation of the influence of 24-h urine storage at moderate temperatures on BRI
Article
Licensed
Unlicensed Requires Authentication

Analytical precision of the Urolizer® for the determination of the BONN-Risk-Index (BRI) for calcium oxalate urolithiasis and evaluation of the influence of 24-h urine storage at moderate temperatures on BRI

  • Wolfgang Berg , Robin Bechler and Norbert Laube
Published/Copyright: February 18, 2009

Abstract

Background: Since its first publication in 2000, the BONN-Risk-Index (BRI) has been successfully used to determine the calcium oxalate (CaOx) crystallization risk from urine samples. To date, a BRI-measuring device, the “Urolizer®”, has been developed, operating automatically and requiring only a minimum of preparation. Two major objectives were pursued: determination of Urolizer® precision, and determination of the influence of 24-h urine storage at moderate temperatures on BRI.

Methods: 24-h urine samples from 52 CaOx stone-formers were collected. A total of 37 urine samples were used for the investigation of Urolizer® precision by performing six independent BRI determinations in series. In total, 30 samples were taken for additional investigation of urine storability. Each sample was measured thrice: directly after collection, after 24-h storage at T=21°C, and after 24-h cooling at T=4°C. Outcomes were statistically tested for identity with regard to the immediately obtained results.

Results: Repeat measurements for evaluation of Urolizer® precision revealed statistical identity of data (p<0.05). 24-h storage of urine at both tested temperatures did not significantly affect BRI (p<0.05).

Conclusions: The pilot-run Urolizer® shows high analytical reliability. The innovative analysis device may be especially suited for urologists specializing in urolithiasis treatment. The possibility for urine storage at moderate temperatures without loss of analysis quality further demonstrates the applicability of the BRI method.

Clin Chem Lab Med 2009;47:478–82.


Corresponding author: Norbert Laube, PhD, Deutsches Harnsteinzentrum, Medizinisches Zentrum Bonn, Friedensplatz 16, 53111 Bonn, Germany Phone: +49-228-22720-176, Fax: +49-228-22720-177,

Received: 2008-9-30
Accepted: 2009-1-9
Published Online: 2009-02-18
Published in Print: 2009-04-01

©2009 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Minireview
  2. Risk loci for type 2 diabetes – Quo vadis?
  3. Genetics and Molecular Diagnostics
  4. A common variant in the FTO gene is associated with body mass index in males and postmenopausal females but not in premenopausal females. Czech post-MONICA and 3PMFs studies
  5. Genotype distribution of estrogen receptor α polymorphisms in pregnant women from healthy and preeclampsia populations and its relation to blood pressure levels
  6. Do common genetic variants in endotoxin signaling pathway contribute to predisposition to alcoholic liver cirrhosis?
  7. The selection and application of ssDNA aptamers against MPT64 protein in Mycobacterium tuberculosis
  8. Stromal cell-derived factor-1 but not its receptor, CXCR4, gene variants increase susceptibility and pathological development of hepatocellular carcinoma
  9. Expression of lineage markers using real-time quantitative polymerase chain reaction (RT-qPCR) in normal and in leukemia bone marrow
  10. Translation termination and protein folding pathway genes are not correlated in gastric cancer
  11. General Clincial Chemistry and Laboratory Medicine
  12. Novel serum paraoxonase activity assays are associated with coronary artery disease
  13. Elevated erythrocyte carbonic anhydrase activity is a novel clinical marker in hyperventilation syndrome
  14. Elevation of the glycoxidation product Nε-(carboxymethyl)lysine in patients presenting with acute myocardial infarction
  15. Lipoprotein(a) level and its association with tumor stage in male patients with primary lung cancer
  16. A high-performance liquid chromatography method for the determination of carbamazepine and carbamazepine-10,11-epoxide and its comparison with chemiluminescent immunoassay
  17. Reference Values and Biological Variations
  18. Minimizing the effects of multicollinearity in the polynomial regression of age relationships and sex differences in serum levels of pregnenolone sulfate in healthy subjects
  19. Determination of physiological plasma pentraxin 3 (PTX3) levels in healthy populations
  20. Validation and Outcome Studies
  21. Analytical precision of the Urolizer® for the determination of the BONN-Risk-Index (BRI) for calcium oxalate urolithiasis and evaluation of the influence of 24-h urine storage at moderate temperatures on BRI
  22. Determination of nitrotyrosine concentrations in plasma samples of diabetes mellitus patients by four different immunoassays leads to contradictive results and disqualifies the majority of the tests
  23. Estimation of trueness of measurement results obtained in external quality assessment
  24. Letters to the Editor
  25. A new PCR-RFLP assay for –1123 G>C polymorphism in the PTPN22 gene: allele and genotype frequencies in a western Mexican population
  26. Proposed classification of various limit values (guide values) used in assisting the interpretation of quantitative laboratory test results
  27. Case report: Over-substitution of thyroxine due to interference in serum thyroid-stimulating hormone measurement
  28. Rv2629 191A/C nucleotide change is not associated with rifampicin resistance in Mycobacterium tuberculosis
Downloaded on 5.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2009.099/html
Scroll to top button